ARTICLE | Company News
Juno gets ADORA2A inhibitor in RedoxTherapies takeout
July 14, 2016 7:00 AM UTC
Juno Therapeutics Inc. (NASDAQ:JUNO) acquired RedoxTherapies Inc. (Boston, Mass.) for $10 million in upfront cash and undisclosed milestones. The deal gives Juno vipadenant (V2006), a small molecule adenosine A2A receptor (ADORA2A) antagonist.
Juno said vipadenant may disrupt immunosuppressive pathways in the tumor microenvironment. The company plans to study vipadenant in combination with its engineered T cells. ...
BCIQ Target Profiles